SKU: T001  / 
    CAS Number: 89786-04-9


    $79.51 - $345.33

    Tazobactam is a penicillanic acid sulfone derivative and beta-lactamase inhibitor with antibacterial activity. Tazobactam was discovered by Dr. R.G. Micetech at the University of Alberta in 1982. Tazobactam contains a beta-lactam ring and irreversibly binds to beta-lactamase at or near its active site. This protects other beta-lactam antibiotics from beta-lactamase catalysis. This drug is used in conjunction with beta-lactamase susceptible penicillins to treat infections caused by beta-lactamase producing organisms.

    Tazobactam alone showed an MIC of ≤ 8 mg/liter (range 2 to 32 mg/liter) against several Acinetobacter baumannii strains. Tazobactam in combination with piperacillin, successfully restored the activity of piperacillin against β-lactamase-producing bacteria. Tazobactam exhibited inhibitory activity and protected piperacillin against Richmond and Sykes types II, III, IV and V β-lactamases, staphylococcal penicillinase and extended-spectrum β-lactamases. Tazobactam showed species-specific activity against class I chromosomally-mediated enzymes.

    TOKU-E offers two forms of tazobactam: tazobactam (T001) and tazobactam sodium (T031). Tazobactam is slightly soluble in aqueous solution (9.59 mg/mL). Tazobactam sodium is freely soluble in aqueous solution.

    Mechanism of ActionTazobactam contains a beta-lactam ring that binds strongly to beta-lactamase at or near its activation site, thereby permanently inhibiting enzymatic activity.  This action protects other beta-lactam antibiotics (penicillins, cephalosporins, etc.) from beta-lactamase catalysis, thereby enhancing their antibacterial activity.

    Tazobactam exhibits little useful antimicrobial activity, although weak activity against Acinetobacter spp. and Borrelia burgdorferi has been reported.

    Tazobactam inhibits a wide range of β-lactamases, including the group 2 penicillinases from Staph. aureus, the TEM-1 and SHV-1 β-lactamases, many extended-spectrum enzymes, and the common group 2e cephalosporinases of B. fragilis. Against the group 1 cephalosporinases, activity is strongly influenced by the amount of enzyme produced. The inhibitor-resistant group 2br β-lactamases are poorly inhibited and group 3 metallo-β-lactamases are not inhibited at clinically useful levels. It is a poor inducer of β-lactamases of Gram-positive and Gram-negative organisms.

    Microbiology ApplicationsTazobactam is often combined with the extended-spectrum β-lactam antibiotic piperacillin in the drug zosyn or Tazocin (piperacillin/tazobactam), used in infections due Pseudomonas aeruginosa. Tazobactam broadens the spectrum of piperacillin by making it effective against organisms that express β-lactamase and would normally degrade piperacillin.
    Molecular Formula



    Craig, W.A., and Andes, D.R. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice. Antimicrob. Agents Chemother. 57(4),1577-1582 (2013).

    Wishart, David. "Tazobactam." DrugBank. The Metabolomics Innovation Center, 13 June 2005. Web. 23 Aug. 2012.

    Drawz, S.M., and Bonomo, R.A. Three decades of β-lactamase inhibitors. Clin.Microbiol.Rev. 23(1), 160-201 (2010).

    Zhanel GG, Chung P, Adam H, et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014 Jan;74(1):31-51. PMID: 24352909

    Frase H, Smith CA, Toth M, et al. Identification of products of inhibition of GES-2 beta-lactamase by tazobactam by x-ray crystallography and spectrometry. J Biol Chem. 2011 Apr 22;286(16):14396-409. PMID: 21345789.

    Jones, R.N., Pfaller, M.A., Fuchs, P.C., et al. Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains. Diagn. Microbiol. Infect. Dis. 12(6), 489-494 (1989).

    Bryson, H.M. and Brogden, R.N. 1994. Drugs. 47: 506-535. PMID: 7514977

    MICEscherichia coli (DH5α + pBC-OXA-46)| 4 - ?| 660| Escherichia coli (DH5α + pBC-SK)| 4 - ?| 660|